# Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism

> **NCT06362746** · PHASE3 · RECRUITING · sponsor: **Supergene, LLC** · enrollment: 486 (estimated)

## Conditions studied

- Pulmonary Embolism

## Interventions

- **DRUG:** Non-immunogenic recombinant staphylokinase
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06362746
- **Lead sponsor:** Supergene, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-23
- **Primary completion:** 2028-06-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 486 (ESTIMATED)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06362746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06362746, "Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06362746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*